At this stage, the only thing that can be said conclusively is that NASH treatment would involve combination therapies. Why Developing NASH Therapy Remains A ChallengeÄevelopment of NASH therapies remains a challenge mainly because our current understanding of the pathogenesis of NASH, while much improved, still remains unclear. Our focus ticker is Allergan ( NYSE: AGN), which has a phase 3 candidate. In this article, we will discuss why developing therapies for NASH remains a challenge despite there being some promising drug candidates. This also creates a challenge for developing therapies for NASH. While the understanding of NASH has improved in the past decade-and-a-half, there are still several questions that remain unanswered. In our previous articles in the February NASH series, we discussed the pathogenesis, epidemiology and diagnosis of NAFLD/NASH.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |